BACKGROUND: The HPV prevalence and genotype distribution are important for the estimation of the impact of HPV-based cervical cancer screening and HPV vaccination on the incidence of diseases etiologically linked to HPVs. The HPV genotype distribution varies across different geographical regions. Therefore, we investigated the type-specific HPV prevalence in Czech women and men with anogenital diseases. METHODS: We analyzed 157 squamous cell carcinoma samples, 695 precancerous lesion samples and 64 cervical, vulvar and anal condylomata acuminate samples. HPV detection and typing were performed by PCR with GP5+/6+ primers, reverse line blot assay and sequencing. RESULTS: Thirty different HPV genotypes were detected in our study, HPV 16 being the most prevalent type both in precancerous lesions (45%) and squamous cell carcinomas (59%). In benign lesions, HPV 6 (72%) was the most common type. Altogether, 61% of carcinoma samples and 43% of precancerous lesion samples contained HPV 16 and/or 18. The presence of HPV types related to the vaccinal ones (HPV 31, 45, 33, 52, 58) were detected in 16% of carcinoma samples and 18% of precancerous lesion samples. HPV 16 and/or 18 were present in 76% of cervical cancer samples, 33% of CIN1, 43% CIN2 and 71% of CIN3 samples. HPV types 6 and/or 11 were detected in 84% samples of condylomata acuminate samples. CONCLUSIONS: The prevalence of vaccinal and related HPV types in patients with HPV-associated diseases in the Czech Republic is very high. We may assume that the implementation of routine vaccination against HPV would greatly reduce the burden of HPV-associated diseases in the Czech Republic.

Department of Experimental Virology Institute of Hematology and Blood Transfusion Prague Czech Republic

Zobrazit více v PubMed

Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–19. PubMed

zur Hausen H, Gissmann L, Steiner W, Dippold W, Dreger I. Human papilloma viruses and cancer. Bibl Haematol. 1975. pp. 569–571. PubMed

Ho GY, Burk RD, Klein S, Kadish AS, Chang CJ, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst. 1995;87:1365–1371. PubMed

Gillison ML, Shah KV. Chapter 9: Role of mucosal human papillomavirus in nongenital cancers. J Natl Cancer Inst Monogr. 2003. pp. 57–65. PubMed

de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2007;7:453–459. PubMed

Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer. 2003;89:101–105. PubMed PMC

Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, et al. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:1157–1164. PubMed

Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005;14:467–475. PubMed

Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007;121:621–632. PubMed

Hoots BE, Palefsky JM, Pimenta JM, Smith JS. Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer. 2009;124:2375–2383. PubMed

Smith JS, Backes DM, Hoots BE, Kurman RJ, Pimenta JM. Human papillomavirus type-distribution in vulvar and vaginal cancers and their associated precursors. Obstet Gynecol. 2009;113:917–924. PubMed

De VH, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer. 2009;124:1626–1636. PubMed

Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 2003;88:63–73. PubMed PMC

Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine. 2006;24(Suppl 3):S3–11-S3/25. PubMed

Cancer incidence 2007 in the Czech Republic. UZIS CR, NOR CR. 2010.

Arbyn M, Autier P, Ferlay J. Burden of cervical cancer in the 27 member states of the European Union: estimates for 2004. Ann Oncol 2007. 18:1423–5. PubMed

Bardin A, Vaccarella S, Clifford GM, Lissowska J, Rekosz M, et al. Human papillomavirus infection in women with and without cervical cancer in Warsaw, Poland. Eur J Cancer. 2008;44:557–564. PubMed

Kornya L, Cseh I, Deak J, Bak M, Fulop V. The diagnostics and prevalence of genital human papillomavirus (HPV) infection in Hungary. Eur J Obstet Gynecol Reprod Biol. 2002;100:231–236. PubMed

Kulmala SM, Shabalova IP, Petrovitchev N, Syrjanen KJ, Gyllensten UB, et al. Prevalence of the most common high-risk HPV genotypes among women in three new independent states of the former Soviet Union. J Med Virol. 2007;79:771–781. PubMed

Speich N, Schmitt C, Bollmann R, Bollmann M. Human papillomavirus (HPV) study of 2916 cytological samples by PCR and DNA sequencing: genotype spectrum of patients from the west German area. J Med Microbiol. 2004;53:125–128. PubMed

Tachezy R, Hamsikova E, Hajek T, Mikyskova I, Smahel M, et al. Human papillomavirus genotype spectrum in Czech women: correlation of HPV DNA presence with antibodies against HPV-16, 18, and 33 virus-like particles. J Med Virol. 1999;58:378–386. PubMed

Tachezy R, Mikyskova I, Ludvikova V, Rob L, Kucera T, et al. Longitudinal study of patients after surgical treatment for cervical lesions: detection of HPV DNA and prevalence of HPV-specific antibodies. Eur J Clin Microbiol Infect Dis. 2006;25:492–500. PubMed

Skapa P, Zamecnik J, Hamsikova E, Salakova M, Smahelova J, et al. Human papillomavirus (HPV) profiles of vulvar lesions: possible implications for the classification of vulvar squamous cell carcinoma precursors and for the efficacy of prophylactic HPV vaccination. Am J Surg Pathol. 2007;31:1834–1843. PubMed

Tachezy R, Jirasek T, Salakova M, Ludvikova V, Kubecova M, et al. Human papillomavirus infection and tumours of the anal canal: correlation of histology, PCR detection in paraffin sections and serology. APMIS. 2007;115:195–203. PubMed

Arbyn M, Van Veen EB, Andersson K, Bogers J, Boulet G, et al. Cervical cytology biobanking in Europe. Int J Biol Markers. 2010;25:117–125. PubMed

van den Brule AJ, Pol R, Fransen-Daalmeijer N, Schouls LM, Meijer CJ, et al. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol. 2002;40:779–787. PubMed PMC

IARC Monograph Working Group. Lyon: IARC; 2007. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans.

Bernard HU, Burk RD, Chen Z, Van DK, Hausen H, et al. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology. 2010;401:70–79. PubMed PMC

Munoz N, Bosch FX, de SS, Herrero R, Castellsague X, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518–527. PubMed

Saiki RK, Scharf S, Faloona F, Mullis KB, Horn GT, et al. Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science. 1985;230:1350–1354. PubMed

Eklund C, Zhou T, Dillner J. Global proficiency study of human papillomavirus genotyping. J Clin Microbiol. 2010;48:4147–4155. PubMed PMC

Wentzensen N, Schiffman M, Dunn T, Zuna RE, Gold MA, et al. Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. Int J Cancer. 2009;125:2151–2158. PubMed PMC

Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374:301–314. PubMed

Jenkins D. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention. Gynecol Oncol. 2008;110:S18–S25. PubMed

Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis. 2009;199:926–935. PubMed

Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis. 2009;199:936–944. PubMed

Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, et al. European Guidelines for Quality Assurance in Cervical Cancer Screening. Second edition--summary document. Ann Oncol. 2010;21:448–458. PubMed PMC

Remmerbach TW, Brinckmann UG, Hemprich A, Chekol M, Kuhndel K, et al. PCR detection of human papillomavirus of the mucosa: comparison between MY09/11 and GP5+/6+ primer sets. J Clin Virol. 2004;30:302–308. PubMed

Szostek S, Klimek M, Zawilinska B, Kosz-Vnenchak M. Genotype-specific human papillomavirus detection in cervical smears. Acta Biochim Pol. 2008;55:687–692. PubMed

Shipitsyna E, Zolotoverkhaya E, Kuevda D, Nasonova V, Romanyuk T, et al. Prevalence of high-risk human papillomavirus types and cervical squamous intraepithelial lesions in women over 30 years of age in St. Petersburg, Russia. Cancer Epidemiol. 2011;35:160–164. PubMed

de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11:1048–1056. PubMed

Sabol I, Salakova M, Smahelova J, Pawlita M, Schmitt M, et al. Evaluation of different techniques for identification of human papillomavirus types of low prevalence. J Clin Microbiol. 2008;46:1606–1613. PubMed PMC

Kowalewska M, Szkoda MT, Radziszewski J, Ptaszynski K, Bidzinski M, et al. The frequency of human papillomavirus infection in polish patients with vulvar squamous cell carcinoma. Int J Gynecol Cancer. 2010;20:434–437. PubMed

Garland SM, Insinga RP, Sings HL, Haupt RM, Joura EA. Human papillomavirus infections and vulvar disease development. Cancer Epidemiol Biomarkers Prev. 2009;18:1777–1784. PubMed

Munoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst. 2010;102:325–339. PubMed

Munoz N, Bosch FX, Castellsague X, Diaz M, de SS, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004;111:278–285. PubMed

Aspartate-β-hydroxylase and hypoxia marker expression in head and neck carcinomas: implications for HPV-associated tumors

Trends of cervical tumours amongst women from perspectives of demographic, socioeconomic and geographic indicators: retrospective ecological study in Czechia

HPV typing of high-grade dysplasia (CIN III) in cone biopsies of 38 HPV-vaccinated women

Human papillomavirus type-specific prevalence in the cervical cancer screening population of Czech women